Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate

被引:0
作者
Takeyoshi Itsukuma
Hideki Ishikawa
Mahito Misawa
Shunro Kai
Yoshihiro Fujimori
Kazuhiko Nakagawa
Seiichi Hirota
Ayako Sugihara
Nobuyuki Terada
Hiroshi Hara
机构
[1] Hyogo College of Medicine,Division of Hematology
[2] Graduate School of Medical Science,Oncology, Department of Internal Medicine
[3] Kyoto Prefectural University of Medicine,Department of Molecular
[4] Hyogo College of Medicine,Targeting Cancer Prevention
[5] Institute of Advanced Medical Sciences,Division of Transfusion Medicine
[6] Hyogo College of Medicine,Laboratory of Cell Transplantation
[7] Houai Hospital,Department of Surgery
[8] Hyogo College of Medicine,Department of Surgical Pathology
[9] Hyogo College of Medicine,First Department of Pathology
[10] Uegahara Hospital,undefined
来源
Journal of Gastroenterology | 2007年 / 42卷
关键词
familial adenomatous polyposis; chronic myelogenous leukemia; imatinib; regression;
D O I
暂无
中图分类号
学科分类号
摘要
Familial adenomatous polyposis (FAP) is an autosomal dominant disorder characterized by colonic polyposis and a predisposition for developing colorectal cancer. FAP is frequently complicated by extracolonic disease, but complications of leukemia are rare. We present the first case of FAP complicated by chronic myelogenous leukemia (CML) in a 38-year-old man. The patient had numerous adenomas in the colorectum and a family history compatible with FAP. He was diagnosed as having FAP in February 2000. Two years after the diagnosis, he developed leukocytosis with the Philadelphia chromosome abnormality, indicating complication with CML. Imatinib mesylate was administered for the treatment of CML, and hematologic and cytogenetic remission of CML was achieved in 6 months. Numerous polyps, 2 to 3 mm in diameter, observed in the rectum prior to the administration of imatinib, regressed in size, but not in number, after 1 year of treatment with imatinib. Eighteen months later, however, the polyps were enlarged. In this patient, imatinib administration led to the remission of CML and might also have been responsible for the temporary regression of adenomatous polyps of FAP.
引用
收藏
页码:402 / 405
页数:3
相关论文
共 41 条
[1]  
Lal G(2000)Familial adenomatous polyposis Semin Surg Oncol 18 314-23
[2]  
Gallinger S(1999)Familial adenomatous polyposis (FAP) and its gene, Cytogenet Cell Genet 86 99-104
[3]  
Bodmer W(1995)BCR/ABL signal transduction Int J Hematol 61 105-12
[4]  
Tauchi T(1996)Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561-6
[5]  
Broxmeyer HE(2002)Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 645-52
[6]  
Druker BJ(1998)Familial gastrointestinal stromal tumours with germline mutation of the KIT gene Nat Genet 19 323-4
[7]  
Tamura S(1993)Molecular diagnosis of familial adenomatous polyposis N Engl J Med 329 1982-7
[8]  
Buchdunger E(1981)Acute myelocytic leukemia in two brothers with polyposis coli and carcinoma of the colon Ann Intern Med 95 702-3
[9]  
Ohno S(2000)Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 139-45
[10]  
Segal GM(2004)COX-2 inhibition and colorectal cancer Semin Oncol 31 12-21